NCT01583426 - Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) | Biotech Hunter

Enrollment

1,229

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions

Tubular Breast Cancer Stage IIMucinous Breast Cancer Stage IIBreast Cancer Female NOSInvasive Ductal Breast CancerTubular Breast Cancer Stage IIIHER-2 Positive Breast CancerInflammatory Breast Cancer Stage IVInflammatory Breast Cancer

Interventions

DRUG

nab-Paclitaxel

nab-Paclitaxel 125 mg/m² weekly for 12 weeks

DRUG

Paclitaxel

Paclitaxel 80 mg/m² weekly for 12 weeks

Trial Locations (1)

13125

Helios-Klinikum Berlin-Buch, Berlin